Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

Ovarian cancer is one of the most lethal of woman cancers, and its clinical therapeutic outcome currently is unsatisfied. Dinaciclib, a novel small molecule inhibitor of CDK1, CDK2, CDK5 and CDK9, is assessed in clinical trials for the treatment of several types of cancers. In this study, we investi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Chen, Xiu-Xiu, Xie, Feng-Feng, Zhu, Xiu-Jie, Lin, Feng, Pan, Shi-Shi, Gong, Li-Hua, Qiu, Jian-Ge, Zhang, Wen-Ji, Jiang, Qi-Wei, Mei, Xiao-Long, Xue, You-Qiu, Qin, Wu-Ming, Shi, Zhi, Yan, Xiao-Jian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2015
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4558126/
https://ncbi.nlm.nih.gov/pubmed/25962959
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller